

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

January 21, 2014

Bombay Stock Exchange Limited

1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited

Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We enclose herewith a copy of press release dated January 21, 2014 under the title “**Zydus receives final approval for Bupropion Hcl ER tablets**” to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



**UPEN H. SHAH
COMPANY SECRETARY**

Encl.: As above.

Zydus receives final approval for Bupropion Hcl ER tablets

Ahmedabad, 21 January 2014

Zydus Cadila has received the final approval from the USFDA to Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment.

The estimated sales in 2013 as per IMS for Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg was USD 255.9 million. The total market for Bupropion was estimated at USD 526.7 million.

The group now has 87 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.
